Pharmacopsychia:在治疗抑郁症疼痛方面,文拉法辛是否比艾司西酞普兰和去甲替林更有效?

2017-11-29 佚名 大话精神

原因不明的疼痛躯体症状(UPPS)通常是由重度抑郁症患者报告的,约有50%-70%的抑郁症患者经历了不同原因的疼痛

原因不明的疼痛躯体症状(UPPS)通常是由重度抑郁症患者报告的,约有50%-70%的抑郁症患者经历了不同原因的疼痛,而相当大比例的疼痛(42.8%)病因无法确定,因此可以认为是抑郁症的症状之一。有证据表明,抑郁症患者出现疼痛症状后,对抗抑郁药的反应更差,缓解时间更长。

二十世纪六十年代以来,三环类抗抑郁药已被用于治疗慢性疼痛。最近,在2项meta分析中记录了5-羟色胺去甲肾上腺素再摄取抑制剂(SNRIs)在神经病变引起的慢性疼痛中的疗效。SNRIs药物度洛西汀,米那普仑和文拉法辛似乎也能有效治疗纤维肌痛,这是一种功能性躯体综合征,伴有不明原因的疼痛,这种综合征常伴有抑郁症状。

迄今为止,不同作用机制的抗抑郁药物对抑郁症中UPPS的疗效,存在相互矛盾的数据。本研究的目的是比较艾司西酞普兰(ESC),去甲替林(NOR)和文拉法辛(VEN)对重度抑郁患者UPPS的影响。

方法

根据ICD-10标准诊断为抑郁症的60名患者(44名女性和16名男性)被随机分配接受艾司西酞普兰(10-30mg,平均剂量15.2,标准差[SD]±9.2)或去甲替林(50-150mg,平均剂量106.2,SD±8.2)。此外,还包括30名接受文拉法辛的患者(75-225mg,平均剂量181.3,SD±8.8)。在基线(第0天)和整个研究期间(第14,28,42,56天),使用视觉模拟评分(VAS)监测疼痛的严重程度。

结果

患者的人口统计学和临床特征见表1。



在试验之前,患者报告的疼痛症状,最常见的部位是头部(71.1%),其次是腹部(26.7%),胸部(26.7%)和颈部(23%)。在整个研究中,三个治疗组患者的总VAS评分显著下降,在第0天至第14天尤为显著。在第2,4,6和8周时,三组间的疼痛强度没有差异,见表2。



在第14天,艾司西酞普兰组的疼痛强度降低了83.6%,去甲替林组降低了67%,文拉法辛组降低了78%。第56天时,抑郁症缓解率(HAMD评分≤7分)艾司西酞普兰组为33.3%,去甲替林组为46.67%,文拉法辛组为66.6%。

总之,在第0,14,28,42和56天,三个治疗组患者的疼痛强度没有显著差异(R vs.NR: [ESC:3.7cm vs.7.7cm, Z=0.97, p=0.33], [NOR:R 3.0cm vs. NR 5.4cm, Z=1.23, p=0.21], [VEN:R 5.4cm vs.NR 6.2cm, Z=0.22, p=0.82]。

讨论

抑郁症中UPPS的发病机制复杂,包括调控情绪,疼痛加工的共同脑网络功能障碍。下行的5-羟色胺和去甲肾上腺素神经元与头端延髓腹内侧和中脑导水管周围灰质相连,对疼痛有调节作用。

研究结果表明,SSRI药物艾司西酞普兰,选择性去甲肾上腺素去甲替林和SNRI药物文拉法辛对MDD患者的疼痛症状起到了相同的作用,对疼痛程度的改善没有达到临床差异。除了第56天文拉法辛治疗的患者的HAMD评分较低外,三组患者的症状缓解程度相当。

在我们的患者中,治疗前2周内疼痛减轻>50%,而抑郁症状大于50%的改善出现的稍晚。这些观察结果可以提供证据表明,抗抑郁药对疼痛和抑郁症的作用是部分独立的,这与Marangell等人的研究结果一致。

此外,一些数据表明,较高剂量的文拉法辛(Debonnel G的研究,每日最大剂量限制在225 mg)可能对UPPS更有效,这可能是由于更多的去甲肾上腺素能作用。

总之,对于抑郁症患者疼痛症状改善方面,本研究结果不支持文拉法辛优于艾司西酞普兰和去甲替林的假设。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1908368, encodeId=e6c3190836889, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 20 16:00:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787393, encodeId=21151e87393f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 04 21:00:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632512, encodeId=540c1632512e3, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Jun 09 04:00:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996100, encodeId=c9691996100d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Dec 03 00:00:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946487, encodeId=2003194648e0e, content=<a href='/topic/show?id=bd853e2622a' target=_blank style='color:#2F92EE;'>#去甲替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37262, encryptionId=bd853e2622a, topicName=去甲替林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Tue Feb 13 06:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265974, encodeId=4aca2659e4bf, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Dec 01 16:12:06 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568388, encodeId=a99d156838882, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Dec 01 13:00:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265640, encodeId=0775265640af, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Nov 30 11:20:35 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265634, encodeId=ce6026563406, content=文拉与西酞与抑郁疼痛, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Nov 30 11:17:38 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023888, encodeId=43fe202388889, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 05 18:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1908368, encodeId=e6c3190836889, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 20 16:00:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787393, encodeId=21151e87393f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 04 21:00:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632512, encodeId=540c1632512e3, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Jun 09 04:00:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996100, encodeId=c9691996100d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Dec 03 00:00:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946487, encodeId=2003194648e0e, content=<a href='/topic/show?id=bd853e2622a' target=_blank style='color:#2F92EE;'>#去甲替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37262, encryptionId=bd853e2622a, topicName=去甲替林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Tue Feb 13 06:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265974, encodeId=4aca2659e4bf, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Dec 01 16:12:06 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568388, encodeId=a99d156838882, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Dec 01 13:00:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265640, encodeId=0775265640af, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Nov 30 11:20:35 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265634, encodeId=ce6026563406, content=文拉与西酞与抑郁疼痛, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Nov 30 11:17:38 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023888, encodeId=43fe202388889, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 05 18:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2018-11-04 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1908368, encodeId=e6c3190836889, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 20 16:00:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787393, encodeId=21151e87393f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 04 21:00:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632512, encodeId=540c1632512e3, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Jun 09 04:00:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996100, encodeId=c9691996100d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Dec 03 00:00:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946487, encodeId=2003194648e0e, content=<a href='/topic/show?id=bd853e2622a' target=_blank style='color:#2F92EE;'>#去甲替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37262, encryptionId=bd853e2622a, topicName=去甲替林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Tue Feb 13 06:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265974, encodeId=4aca2659e4bf, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Dec 01 16:12:06 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568388, encodeId=a99d156838882, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Dec 01 13:00:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265640, encodeId=0775265640af, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Nov 30 11:20:35 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265634, encodeId=ce6026563406, content=文拉与西酞与抑郁疼痛, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Nov 30 11:17:38 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023888, encodeId=43fe202388889, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 05 18:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1908368, encodeId=e6c3190836889, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 20 16:00:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787393, encodeId=21151e87393f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 04 21:00:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632512, encodeId=540c1632512e3, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Jun 09 04:00:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996100, encodeId=c9691996100d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Dec 03 00:00:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946487, encodeId=2003194648e0e, content=<a href='/topic/show?id=bd853e2622a' target=_blank style='color:#2F92EE;'>#去甲替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37262, encryptionId=bd853e2622a, topicName=去甲替林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Tue Feb 13 06:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265974, encodeId=4aca2659e4bf, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Dec 01 16:12:06 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568388, encodeId=a99d156838882, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Dec 01 13:00:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265640, encodeId=0775265640af, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Nov 30 11:20:35 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265634, encodeId=ce6026563406, content=文拉与西酞与抑郁疼痛, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Nov 30 11:17:38 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023888, encodeId=43fe202388889, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 05 18:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2017-12-03 yb6560
  5. [GetPortalCommentsPageByObjectIdResponse(id=1908368, encodeId=e6c3190836889, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 20 16:00:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787393, encodeId=21151e87393f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 04 21:00:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632512, encodeId=540c1632512e3, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Jun 09 04:00:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996100, encodeId=c9691996100d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Dec 03 00:00:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946487, encodeId=2003194648e0e, content=<a href='/topic/show?id=bd853e2622a' target=_blank style='color:#2F92EE;'>#去甲替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37262, encryptionId=bd853e2622a, topicName=去甲替林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Tue Feb 13 06:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265974, encodeId=4aca2659e4bf, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Dec 01 16:12:06 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568388, encodeId=a99d156838882, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Dec 01 13:00:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265640, encodeId=0775265640af, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Nov 30 11:20:35 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265634, encodeId=ce6026563406, content=文拉与西酞与抑郁疼痛, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Nov 30 11:17:38 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023888, encodeId=43fe202388889, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 05 18:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1908368, encodeId=e6c3190836889, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 20 16:00:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787393, encodeId=21151e87393f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 04 21:00:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632512, encodeId=540c1632512e3, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Jun 09 04:00:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996100, encodeId=c9691996100d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Dec 03 00:00:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946487, encodeId=2003194648e0e, content=<a href='/topic/show?id=bd853e2622a' target=_blank style='color:#2F92EE;'>#去甲替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37262, encryptionId=bd853e2622a, topicName=去甲替林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Tue Feb 13 06:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265974, encodeId=4aca2659e4bf, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Dec 01 16:12:06 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568388, encodeId=a99d156838882, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Dec 01 13:00:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265640, encodeId=0775265640af, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Nov 30 11:20:35 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265634, encodeId=ce6026563406, content=文拉与西酞与抑郁疼痛, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Nov 30 11:17:38 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023888, encodeId=43fe202388889, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 05 18:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2017-12-01 往日如昨

    学习了谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1908368, encodeId=e6c3190836889, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 20 16:00:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787393, encodeId=21151e87393f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 04 21:00:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632512, encodeId=540c1632512e3, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Jun 09 04:00:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996100, encodeId=c9691996100d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Dec 03 00:00:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946487, encodeId=2003194648e0e, content=<a href='/topic/show?id=bd853e2622a' target=_blank style='color:#2F92EE;'>#去甲替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37262, encryptionId=bd853e2622a, topicName=去甲替林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Tue Feb 13 06:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265974, encodeId=4aca2659e4bf, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Dec 01 16:12:06 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568388, encodeId=a99d156838882, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Dec 01 13:00:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265640, encodeId=0775265640af, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Nov 30 11:20:35 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265634, encodeId=ce6026563406, content=文拉与西酞与抑郁疼痛, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Nov 30 11:17:38 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023888, encodeId=43fe202388889, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 05 18:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1908368, encodeId=e6c3190836889, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 20 16:00:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787393, encodeId=21151e87393f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 04 21:00:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632512, encodeId=540c1632512e3, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Jun 09 04:00:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996100, encodeId=c9691996100d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Dec 03 00:00:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946487, encodeId=2003194648e0e, content=<a href='/topic/show?id=bd853e2622a' target=_blank style='color:#2F92EE;'>#去甲替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37262, encryptionId=bd853e2622a, topicName=去甲替林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Tue Feb 13 06:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265974, encodeId=4aca2659e4bf, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Dec 01 16:12:06 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568388, encodeId=a99d156838882, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Dec 01 13:00:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265640, encodeId=0775265640af, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Nov 30 11:20:35 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265634, encodeId=ce6026563406, content=文拉与西酞与抑郁疼痛, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Nov 30 11:17:38 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023888, encodeId=43fe202388889, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 05 18:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2017-11-30 神功盖世

    学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1908368, encodeId=e6c3190836889, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 20 16:00:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787393, encodeId=21151e87393f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 04 21:00:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632512, encodeId=540c1632512e3, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Jun 09 04:00:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996100, encodeId=c9691996100d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Dec 03 00:00:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946487, encodeId=2003194648e0e, content=<a href='/topic/show?id=bd853e2622a' target=_blank style='color:#2F92EE;'>#去甲替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37262, encryptionId=bd853e2622a, topicName=去甲替林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Tue Feb 13 06:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265974, encodeId=4aca2659e4bf, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Dec 01 16:12:06 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568388, encodeId=a99d156838882, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Dec 01 13:00:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265640, encodeId=0775265640af, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Nov 30 11:20:35 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265634, encodeId=ce6026563406, content=文拉与西酞与抑郁疼痛, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Nov 30 11:17:38 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023888, encodeId=43fe202388889, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 05 18:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=)]
    2017-11-30 sunfeifeiyang

    文拉与西酞与抑郁疼痛

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1908368, encodeId=e6c3190836889, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Thu Sep 20 16:00:00 CST 2018, time=2018-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787393, encodeId=21151e87393f8, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Sun Nov 04 21:00:00 CST 2018, time=2018-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632512, encodeId=540c1632512e3, content=<a href='/topic/show?id=edf586e533d' target=_blank style='color:#2F92EE;'>#艾司西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86753, encryptionId=edf586e533d, topicName=艾司西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9e521925158, createdName=zhty5344, createdTime=Sat Jun 09 04:00:00 CST 2018, time=2018-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996100, encodeId=c9691996100d9, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Dec 03 00:00:00 CST 2017, time=2017-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946487, encodeId=2003194648e0e, content=<a href='/topic/show?id=bd853e2622a' target=_blank style='color:#2F92EE;'>#去甲替林#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37262, encryptionId=bd853e2622a, topicName=去甲替林)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Tue Feb 13 06:00:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265974, encodeId=4aca2659e4bf, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Fri Dec 01 16:12:06 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568388, encodeId=a99d156838882, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Dec 01 13:00:00 CST 2017, time=2017-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265640, encodeId=0775265640af, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Thu Nov 30 11:20:35 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265634, encodeId=ce6026563406, content=文拉与西酞与抑郁疼痛, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Thu Nov 30 11:17:38 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023888, encodeId=43fe202388889, content=<a href='/topic/show?id=99ff64628fb' target=_blank style='color:#2F92EE;'>#治疗抑郁#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64628, encryptionId=99ff64628fb, topicName=治疗抑郁)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Mon Mar 05 18:00:00 CST 2018, time=2018-03-05, status=1, ipAttribution=)]

相关资讯

Pharmacoepidemiol Drug Saf:黑框警告前后 儿童和青少年抗抑郁药处方趋势如何?

2017年9月,发表在《Pharmacoepidemiol Drug Saf》上的一项时间序列分析,调查了加拿大初级医疗机构在黑框警告前后,儿童和青少年抗抑郁药(AD)处方的趋势和模式。分析结果显示:黑框警告可有效地降低AD处方,但下降并未持续出现了反弹。

Sci Rep:研究发现,生长在亚马逊的传统药物治疗抑郁症有奇效,不上瘾

一项新的研究指出,迷幻药物通常用于南美,可以改善人们一般意义上的幸福,是治疗酗酒和抑郁的一种选择。

JAMA Psychiatry:妊娠期母亲抗抑郁药物使用会引发后代智力障碍?

2017年10月,发表在《JAMA Psychiatry》的一项由美国、瑞典、加拿大和以色列科学家进行的研究考察了妊娠期抗抑郁药物使用与后代智力障碍(ID)之间的相关性。

Brain Behav Immun:抑郁症恢复的希望!科学研究发现:抑郁症的诊断和治疗需要进行重大调整,因为目前的抑郁症治疗无效,缺乏

《大脑、行为和免疫》的一篇新评论文章的作者说,抑郁症的诊断和治疗需要进行重大调整。

Aust Psycho:男性抑郁症患者需要区别对待

虽然严重抑郁障碍的患病率继续上升,但许多男性仍未寻求和维持治疗。澳大利亚悉尼大学的新研究显示,如果男性抑郁症患者越来越多的接受精神卫生服务,那么治疗男性抑郁症的方法需要改变。

Diabetologia:抑郁症和糖尿病困扰与血糖控制和糖尿病并发症的关联如何?

近日,国际杂志 《Diabetologia》上在线发表一项关于新诊断的2型糖尿病超过2年时间内,其抑郁症状与血糖控制和糖尿病并发症困扰关系的前瞻性队列研究。在诊断为2型糖尿病后,研究人员检查了2年以上抑郁症状与糖尿病并发症和血糖控制困扰的关系。